Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 1Melanoma 1Locally Advanced Rectal Adenocarcinoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 69Nivolumab 69cabozantinib 45Ipilimumab 38Specimen Handling 33Magnetic Resonance Spectroscopy 33lenvatinib 26Axitinib 25belzutifan 21Sunitinib 18Biopsy 15Radiosurgery 14CTLA-4 Antigen 13atezolizumab 12Everolimus 10pazopanib 8fludarabine 8avelumab 8Bevacizumab 8toripalimab 7cemiplimab 7Nephrectomy 7Immunoglobulin G 7Cyclophosphamide 7aldesleukin 6Standard of Care 6Radiotherapy 6Blood Specimen Collection 6spartalizumab 5palbociclib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × sotigalimab × 1 year × Clear all
NCT04495257 2025-10-30

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Yale University

Phase 1 Active not recruiting
26 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡